Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C6H5O7.3Ca.4H2O |
| Molecular Weight | 570.495 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=LNIZKKFWMDARJV-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Ca.4H2O/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;4*1H2/q;;3*+2;;;;/p-6
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat. | 1999 Apr |
|
| Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension? | 1999 Jul 30 |
|
| Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
| Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes. | 1999 Sep |
|
| Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
| Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. | 2000 Aug |
|
| Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. | 2000 Aug |
|
| Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. | 2000 Feb 11 |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. | 2000 Jan 1 |
|
| NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. | 2000 Jul 17 |
|
| ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
| Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
| Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. | 2001 Jul |
|
| Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
| Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy. | 2001 Jun 8 |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
| RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001 Sep 1 |
|
| A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein. | 2001 Sep 15 |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
| Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
| Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 184.1195
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-VATC |
QA12AA09
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-ATC |
A12AA09
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-ATC |
A12AA13
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-VATC |
QA12AA13
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11093
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
SUB16376MIG
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
5282392
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
D019355
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106123
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
C1355
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
m2933
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000087584
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
SUB13170MIG
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
5785-44-4
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
4479
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
CALCIUM CITRATE
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
MLM29U2X85
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
47613
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
MLM29U2X85
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
1086414
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
DTXSID40893034
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
